scroll down

Medical Insurance Bureau: Bypassing hospitals to settle accounts directly with medical device companies

2020-04-30

Methods by which medical insurance improves the efficiency of medical institution billing; medical institutions will lose the right to directly settle payments with enterprises.

Analysis of the Current Status of the Traditional Chinese Medicine Diagnostic and Therapeutic Equipment Industry in China

2020-04-30

Many traditional Chinese medicine (TCM) practitioners face significant challenges in TCM diagnosis. For the future of TCM in our country, there are at least "three mountains" to overcome, including increasing the industrial foundation for TCM instruments, unifying industry consensus on TCM instrument systems, and gradually improving the standardized system for TCM instruments.

7.7 Billion! China's Mask Exports Boom

2020-04-09

As of April 5, China has signed commercial procurement contracts for medical supplies with 54 countries and 3 international organizations, and has released export goods worth 10.2 billion yuan for major epidemic prevention and control.

How open is China's medical sector in Boao? Global pharmaceuticals and medical devices directly reaching patients

2020-04-09

More than 10 well-known multinational pharmaceutical and medical device manufacturers have written letters seeking cooperation. The first imported medical device in China to use real-world data from Boao Lecheng has been approved for market launch, and the country's first medical insurance with reimbursement for special domestic and foreign drugs has been implemented. Despite the pandemic, the Boao Lecheng International Medical Tourism Pilot Zone in Hainan continues to make progress, continuously pushing the opening of China's medical opening window wider and wider.

China's medical device industry will enter a peak period of mergers and acquisitions

2020-04-03

Recently, a reporter from the Securities Daily interviewed experts from the National Medical Products Administration's Southern Institute of Pharmaceutical Economics (hereinafter referred to as "Southern Institute") regarding the current status, development prospects, and challenges facing the medical device industry in China.

Changes and Development Opportunities in the Medical Device Industry Post-Pandemic

2020-03-23

Under the COVID-19 pandemic, all walks of life have been severely impacted. Some say that the medical device industry has benefited from the adversity. Is this really the case? How will our medical device industry go after the epidemic? Overall domestic and international industry status and demand 1. Analysis of the current situation of China's medical industry From a short-term perspective, the epidemic has made the pharmaceutical industry highly sought after. After the Spring Festival, pharmaceutical stocks hit the daily limit 201 times in 5 days, and the medical device sub-sector rose by as much as 10.61%, while the medical service sub-sector, which had a smaller increase, also rose by 3.92%. With the amplified demand for related pharmaceutical products, the demand suppressed by the epidemic in the short term will also be gradually released. In 2020, China's medical and health

The National Medical Products Administration revised and released the "Management Measures for Quality Spot Checks and Inspections of Medical Devices"

2020-03-20

To strengthen the post-market supervision and management of medical devices and further improve the medical device sampling inspection work, the National Medical Products Administration (NMPA) organized the revision of the original "Regulations on the Supervision and Inspection of Medical Device Quality" (Food and Drug Administration Medical Device Supervision [2013] No. 212), and issued the "Measures for the Quality Sampling Inspection of Medical Devices" on March 10, 2020. The Measures consist of 7 chapters and 47 articles, including general provisions, plans and programs, inspection sampling, inspection management and report delivery, re-inspection and disposal, supervision and management, and supplementary provisions. The overall idea of the revision is to clarify the responsibilities and requirements of the drug regulatory departments at all levels for sampling inspection work in conjunction with institutional reforms; to emphasize problems
< 1...131415...36 >